|
WO2008153937A2
|
|
Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
|
|
WO2008063673A1
|
|
Methods and compositions for controlling body weight and appetite
|
|
NZ572247A
|
|
Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and intermediate compounds of the process
|
|
AU2006272623A1
|
|
Methods and compositions for the treatment of neuropathies and related disorders
|
|
ZA200801825B
|
|
Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
|
|
CN101272684A
|
|
Methods and compositions for the treatment of neuropathies and related disorders
|
|
EP1874298A2
|
|
Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3,1,0]hexanes
|
|
EP1807071A2
|
|
Antipyretic compositions and methods
|
|
AU2005277351A1
|
|
Novel polymorphs of azabicyclohexane
|
|
ZA200504459B
|
|
Polymorphs of bicifadine hydrochloride
|
|
ZA200607796B
|
|
2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazol[1,5-a]pyrimidin-3-yl]methanones
|
|
EP1562900A1
|
|
Polymorphs of bicifadine hydrochloride
|
|
WO03017927A2
|
|
(-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
|
|
US2002172694A1
|
|
Extended release formulation of diltiazem hydrochloride
|
|
US6372919B1
|
|
(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
|
|
US6162463A
|
|
Extended release formulation of diltiazem hydrochloride
|
